SAR440340

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

11 competitors in Chronic Rhinosinusitis With Nasal Polyps

#DrugCompanyPhaseTrials

1

Asmanex

PPerrigo Company

Approved

52

Nucala

GGlaxo Dba Glaxosmithkline

Approved

53

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Approved

34

Tezspire

AstraZeneca

Phase 3

35

Stapokibart

CChengdu Kangnuoxing Biopharma,Inc.

Phase 3

26

Lunsekimig

Sanofi

Phase 2

27

Itepekimab AI

Sanofi

Phase 3

48

SHR-1905

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 3

29

LP-003

LLongbio Pharma

Phase 2

110

SAR440340

Sanofi

Phase 3

2Show 2 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease2 trials

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Completed·Sanofi·Phase 2·NCT03546907·343 enrolled

A Double-blinded Extension Study to Evaluate the Long-term Safety and Tolerability of Itepekimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Participated in Either EFC16750 or EFC16819 Clinical Studies

Completed·Sanofi·Phase 3·NCT06208306·669 enrolled

Chronic Rhinosinusitis With Nasal Polyps2 trials

A Randomized, Double-blind, Parallel-group, 52-week Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

Withdrawn·Sanofi·Phase 3·NCT07484230

A Double-blinded Extension Study to Evaluate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Participated in Either EFC18418 or EFC18419 Clinical Studies

Active, not recruiting·Sanofi·Phase 3·NCT07424144·59 enrolled

Asthma1 trial

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

Completed·Sanofi·Phase 2·NCT03387852·296 enrolled

Chronic Rhinosinusitis Without Nasal Polyps1 trial

A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps

Completed·Sanofi·Phase 2·NCT06691113·66 enrolled

Details

Drug Info

Related News